Valneva (NASDAQ:VALN) Rating Lowered to “Sell” at Wall Street Zen

Valneva (NASDAQ:VALN) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

VALN has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Valneva in a report on Wednesday, October 8th. Jefferies Financial Group set a $14.00 price objective on Valneva and gave the stock a “buy” rating in a report on Monday, August 25th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Valneva in a research note on Monday, August 25th. Finally, Guggenheim reduced their price target on Valneva from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Monday, September 8th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Valneva presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Valneva Stock Performance

NASDAQ VALN opened at $8.90 on Friday. Valneva has a 52-week low of $3.62 and a 52-week high of $12.25. The company has a fifty day moving average of $9.64 and a 200-day moving average of $8.38. The company has a market capitalization of $765.22 million, a P/E ratio of -6.18 and a beta of 1.83. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.36 and a current ratio of 1.78.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Thursday, November 20th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.31). The firm had revenue of $34.01 million for the quarter, compared to analysts’ expectations of $48.85 million. Valneva had a negative net margin of 57.81% and a negative return on equity of 59.44%. As a group, equities research analysts predict that Valneva will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Valneva

A number of large investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. bought a new position in shares of Valneva during the second quarter valued at approximately $8,240,000. Marex Group plc purchased a new position in Valneva during the 2nd quarter valued at $64,000. JPMorgan Chase & Co. bought a new position in Valneva in the 3rd quarter worth $124,000. Finally, VSM Wealth Advisory LLC lifted its position in shares of Valneva by 125.0% in the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after purchasing an additional 5,000 shares during the period. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.